FDA has issued emergency use authorizations (EUAs) to Hologic, Marlborough, Mass, for its Panther Fusion SARS-CoV-2 assay and to Laboratory Corporation of America (LabCorp), Burlington, NC, for its Covid-19 RT-PCR test.
Stephen M. Hahn, MD, FDA.
“Staff at FDA have been working nonstop to expedite the review and authorization of diagnostics during this public health emergency,” says FDA Commissioner Stephen M. Hahn, MD. “Our device center has been in continual contact with the medical device community, in particular diagnostic developers, since January—providing technical assistance to test developers to help facilitate the availability and distribution of tests so that healthcare professionals can accurately detect the covid-19 virus. Since the beginning of this outbreak, more than 90 test developers have sought FDA guidance with the development and validation of tests they plan to bring through the EUA process. Additionally, more than 40 laboratories have notified us that they are testing or intend to begin testing soon under our new policy for laboratory-developed tests for this emergency. We stand ready to continue to support medical products in the pipeline to fight this virus.”
Read more at FDA.
